Advanced Drug Delivery Systems Market Report 2026

Advanced Drug Delivery Systems Market Overview

• Advanced Drug Delivery Systems market size has reached to $285.59 billion in 2025 • Expected to grow to $433.56 billion in 2030 at a compound annual growth rate (CAGR) of 8.7% • Growth Driver: The Surge In Chronic Conditions Fuels Growth Of The Advanced Drug Delivery Systems Market • Market Trend: Driving Innovation in Drug Delivery Methods for Enhanced Patient Care • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Advanced Drug Delivery Systems Market?

Advanced drug delivery systems refer to innovative techniques and formulations that improve pharmaceutical medications' targeted distribution, bioavailability, and efficacy. These systems maximize drug efficacy and minimize side effects, control the drug release rate, and target specific body areas. The main types of advanced drug delivery systems are oral drug delivery systems, injection-based drug delivery systems, inhalation or pulmonary drug delivery system, transdermal drug delivery system, transmucosal drug delivery system, carrier-based drug delivery systems, and others. The oral drug delivery system refers to the process of introducing a chemical through the mouth or into the gastrointestinal tract, typically for systemic activity. The carrier types are liposomes, nanoparticles, microspheres, monoclonal antibodies, and others. It employs technology such as prodrugs, implants, intrauterine devices, targeted drug delivery, polymeric drug delivery, and others. These delivery systems are used for indicate cardiovascular diseases, oncology, urology, diabetes, CNS (central nervous system), ophthalmology, inflammatory diseases, infections, and others, which are used by hospitals, specialized clinics, clinical research and development centers.

What Is The Advanced Drug Delivery Systems Market Growth Forecast?

The advanced drug delivery systems market size is expected to see strong growth in the next few years. It will grow to $433.56 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, rising adoption of biologics, expansion of nanotechnology-based therapies, growing focus on reducing drug side effects, increasing investments in advanced pharmaceutical delivery platforms. Major trends in the forecast period include increasing adoption of targeted drug delivery technologies, rising use of nanocarrier-based formulations, growing demand for controlled release systems, expansion of biologic and biosimilar delivery solutions, enhanced focus on patient-centric drug administration.

Global Advanced Drug Delivery Systems Market Segmentation

1) By Type: Oral Drug Delivery System, Injection-Based Drug Delivery System, Inhalation Or Pulmonary Drug Delivery System, Transdermal Drug Delivery System, Transmucosal Drug Delivery System, Carrier-Based Drug Delivery System, Other Types 2) By Carrier Type: Liposomes, Nanoparticles, Microspheres, Other Carrier Types 3) By Technology: Prodrug, Implants And Intrauterine Devices, Targeted Drug Delivery, Polymeric Drug Delivery, Other Technologies 4) By Application: Cardiovascular Diseases, Oncology, Urology, Diabetes, CNS (Central Nervous System), Ophthalmology, Inflammatory Diseases, Infections, Other Applications 5) By End User: Hospitals, Specialized clinics, Clinical Research And Development Centers Subsegments: 1) By Oral Drug Delivery System: Solid Dosage Forms, Liquid Dosage Forms, Novel Oral Delivery Systems 2) By Injection-Based Drug Delivery System: Autoinjectors, Microneedle-Based Systems 3) By Inhalation Or Pulmonary Drug Delivery System: Metered-Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Nebulizers, Soft Mist Inhalers 4) By Transdermal Drug Delivery System: Transdermal Patches, Microneedle Patches, Iontophoresis Systems 5) By Transmucosal Drug Delivery System: Buccal Delivery Systems, Sublingual Delivery Systems, Nasal Delivery Systems 6) By Carrier-Based Drug Delivery System: Liposomes, Nanoparticles, Dendrimers, Niosomes 7) By Other Types: Implantable Drug Delivery Systems, Targeted Delivery Systems, Bioadhesive Drug Delivery Systems

What Is The Driver Of The Advanced Drug Delivery Systems Market?

The increasing prevalence of chronic conditions is expected to propel the growth of the advanced drug delivery systems market going forward. Chronic conditions are problems that last a year or longer, necessitating continuing medical care, restricting everyday activities, or both. Various risk behaviors, including tobacco use and exposure to secondhand smoke, poor nutrition, physical inactivity, and excessive alcohol use, cause chronic diseases. Advanced drug delivery systems allow targeted delivery of therapeutic agents to specific sites in the body affected by chronic conditions. They ensure the drug reaches the intended site of action, increasing its effectiveness and minimizing side effects. For instance, in May 2023, according to The United Nations (UN), a US-based intergovernmental organization to promote international cooperation and maintain international peace and security, Chronic diseases are responsible for seven out of 10 deaths in the US, killing more than 1.7 million Americans each year. Therefore, the increasing prevalence of chronic conditions is driving the growth of the advanced drug delivery systems industry.

Key Players In The Global Advanced Drug Delivery Systems Market

Major companies operating in the advanced drug delivery systems market are Pfizer Inc., Johnson and Johnson Services Inc., Roche Holding AG, Abbvie Inc., Bayer AG, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, 3M Company, Medtronic plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Amgen Inc., Merck Group, Becton Dickinson and Company, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Boston Scientific Corporation, Astellas Pharma Inc., Catalent Inc., Nipro Corporation, AptarGroup Inc., West Pharmaceutical Services Inc., Gerresheimer AG, Insulet Corporation

Global Advanced Drug Delivery Systems Market Trends and Insights

Major companies operating in the advanced drug delivery system market are focusing on developing innovative solutions, such as subcutaneous biologic delivery technologies, to meet the rising demand for convenient, rapid, and patient-friendly administration of complex therapies. Subcutaneous biologic delivery enables high-volume drug administration under the skin, offering a less invasive alternative to traditional intravenous infusion. For instance, in June 2023, Halozyme Therapeutics, Inc., a US-based biopharmaceutical company, announced the FDA approval of VYVGART Hytrulo with ENHANZE, an innovative subcutaneous formulation for generalized myasthenia gravis. The product combines efgartigimod alfa with Halozyme’s recombinant human hyaluronidase PH20 (rHuPH20), enabling rapid, high-volume subcutaneous delivery in a single injection. It reduces infusion time to seconds, improves patient convenience, supports treatment outside hospital settings, and maintains clinical efficacy comparable to IV administration.

What Are Latest Mergers And Acquisitions In The Advanced Drug Delivery Systems Market?

In November 2023, Acumen Pharmaceuticals, Inc., a US-based clinical-stage biopharmaceutical company developing therapies for Alzheimer’s disease, partnered with Halozyme Therapeutics, Inc. to develop a subcutaneous formulation of ACU193 using ENHANZE technology. Through this partnership, Acumen and Halozyme aim to advance patient-centric drug delivery by enabling a more convenient and effective subcutaneous administration of ACU193 while maintaining therapeutic efficacy. Halozyme Therapeutics, Inc. is a US-based biopharmaceutical company that provides drug delivery solutions, including ENHANZE technology, which facilitates subcutaneous delivery of biologics and reduces treatment burden for patients.

Regional Outlook

North America was the largest region in the advanced drug delivery systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Advanced Drug Delivery Systems Market?

The advanced drug delivery systems market consists of revenues earned by entities by providing stimuli-responsive drug delivery systems, sustained drug delivery systems, targeted drug delivery systems, and nanoparticle-based drug delivery systems. The market value includes the value of related goods sold by the service provider or included within the service offering. The advanced drug delivery systems market also consists of sales of fentanyl transdermal patches, albuterol inhalers, and hydrogels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.